(Boursier.com) — Breaking data presented by Sanofi at the 2024 AAAAI Congress show that rilzabrutinib, an oral BTK inhibitor, significantly reduces the ISS7 score (weekly pruritus intensity score), from the first week of treatment, in adults with Moderate to severe UCS. Positive results from the Phase II RILECSU study show that rilzabrutinib significantly relieves itching and urticaria in adults with moderate to severe chronic spontaneous urticaria (CSU), whose symptoms are inadequately controlled with antihistamines. H1.
These results were presented as a poster at the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) Congress in Washington, DC and form the basis of the Phase III program expected to begin in 2024 in the treatment of UCS and prurigo nodularis, which will begin in 2024.
Results from pivotal Phase III trials in the treatment of immune thrombocytopenia and Phase II trials in asthma, IgG4 disease and autoimmune hemolytic anemia are expected in 2024.
Recall that rilzabrutinib is one of 12 potential blockbusters in Sanofi’s cutting-edge immunology development portfolio.
©2024 Boursier.com